Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

by · The Cerbat Gem

Talphera, Inc. (NASDAQ:TLPH – Get Free Report) was the recipient of a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 42,300 shares, a decrease of 19.3% from the September 15th total of 52,400 shares. Based on an average daily volume of 66,600 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.3% of the shares of the stock are short sold.

Talphera Price Performance

Shares of NASDAQ:TLPH traded down $0.01 during midday trading on Friday, hitting $0.79. The company had a trading volume of 35,141 shares, compared to its average volume of 86,377. Talphera has a twelve month low of $0.43 and a twelve month high of $1.61. The stock has a market cap of $13.42 million, a price-to-earnings ratio of -0.89 and a beta of 0.32. The business’s 50-day simple moving average is $0.90 and its 200-day simple moving average is $0.96.

Talphera (NASDAQ:TLPH – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. As a group, sell-side analysts forecast that Talphera will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Turtle Creek Wealth Advisors LLC bought a new stake in Talphera, Inc. (NASDAQ:TLPH – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 71,500 shares of the company’s stock, valued at approximately $64,000. Turtle Creek Wealth Advisors LLC owned about 0.42% of Talphera at the end of the most recent reporting period. Institutional investors and hedge funds own 37.67% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Talphera in a research report on Friday, August 16th.

View Our Latest Research Report on TLPH

Talphera Company Profile

(Get Free Report)

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.

Featured Stories